ReviewEndocrine2019
The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment.
Review in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [SEIOMM-SEMERGEN-semFYC-SEMG recommendations for the management of patients with osteoporosis/fragility fracture in primary care].Atencion primaria · 2026Guideline
- Bone Mineral Density After Transitioning From Denosumab to Alendronate.The Journal of clinical endocrinology and metabolism · 2020Trial
- Modern pharmacological management of Osteoporosis: from monotherapy to sequential and combination approaches in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Review
- Modern Strategies for Osteoporosis Therapy: Current Status and Prospects for Targeted Intervention.International journal of molecular sciences · 2025Review
- Dusp1 in osteolytic diseases-mechanisms and therapeutic potential.Scientific reports · 2025Article
- Bone Health for Gynaecologists.Medicina (Kaunas, Lithuania) · 2025Review
- Digital twin simulations with a micro-multiphysics agent-based model reveal key drivers of bone loss after denosumab discontinuation.Frontiers in bioengineering and biotechnology · 2025Article
- Mechanistic Insights and Therapeutic Strategies in Osteoporosis: A Comprehensive Review.Biomedicines · 2024Review
- The Sequential Therapy in Osteoporosis.Indian journal of orthopaedics · 2023Review
- Article
- Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics.International journal of molecular sciences · 2023Review
- Comorbidity and osteoporotic fracture: approach through predictive modeling techniques using the OSTEOMED registry.Aging clinical and experimental research · 2022Observational
- Pain Intensity and Degree of Disability after Fragility Fractures of the Pelvis.Medicina (Kaunas, Lithuania) · 2022Article
- Review
- Osteoporosis: Mechanism, Molecular Target and Current Status on Drug Development.Current medicinal chemistry · 2021Review
- A Review on the Role of Denosumab in Fracture Prevention.Drug design, development and therapy · 2020Review
- [Osteoporosis-specific treatment when and how?]Der Internist · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several antiresorptive drugs, like bisphosphonates and denosumab, are currently available for the treatment of osteoporosis due to their evidenced efficacy in reducing fracture risk at mid-term. Osteoanabolic therapies, like teriparatide, whose treatment duration is limited to 2 years, have also shown efficacy in the reduction of fracture risk. However, depending on the severity of osteoporosis and the presence of other associated risk factors for fracture, some patients may require long-term treatment to preserve optimal bone strength and minimize bone fracture risk. Given the limited duration of some treatments, the fact that most of the antiresorptive drugs have not been assessed beyond 10 years, and the known long-term safety issues of these drugs, including atypical femoral fractures or osteonecrosis of the jaw, the long-term management of these patients may require an approach based on drug discontinuation and/or switching. In this regard, interest in sequential osteoporosis therapy, wherein drugs are initiated and discontinued over time, has grown in recent years, although the establishment of an optimal and individualized order of therapies remains controversial. This review reports the currently available clinical evidence on the discontinuation effects of different anti-osteoporotic drugs, as well as the clinical outcomes of the different sequential treatment regimens. The objective of this article is to present up-to-date practical knowledge on this area in order to provide guidance to the clinicians involved in the management of patients with osteoporosis.
Indexed as
Identifiers
30963388What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.